$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 17.42% on an annualized basis producing an average annual return of 29.68%. Currently, Regeneron
Regeneron Pharma Is Maintained at Neutral by Cantor Fitzgerald
Regeneron Pharma Is Maintained at Neutral by Cantor
HRMY or REGN: Which Is the Better Value Stock Right Now?
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $925
Regeneron Pharmaceuticals (REGN) has an average outperform rating and price target range of $720 to $1,300, according to analysts polled by Capital IQ.Price: 1,069.52, Change: +5.92, Percent Change: +
Express News | Regeneron Pharmaceuticals Inc : Jefferies Raises Target Price to $1,235 From $1,135
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Regeneron Pharmaceuticals's (NYSE:REGN) short percent of float has risen 10.17% since its last report. The company recently reported that it has 2.04 million shares sold short, which is 1.95% of all
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,300 From $1,082, Outperform Rating Maintained
Regeneron Pharmaceuticals (REGN) has an average outperform rating and a price target range of $720 to $1,250, according to analysts polled by Capital IQ.
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,166
Piper Sandler analyst Christopher Raymond maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and adjusts the target price from $1,000 to $1,166.According to TipRanks data, the analyst
Express News | Regeneron Pharmaceuticals Inc : Piper Sandler Raises Target Price to $1,166 From $1,000
Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report
Regeneron Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/18/2024 9.29% Guggenheim $1040 → $1180 Maintains Buy 07/11/2024 9.48% Morgan Stanley $1183 → $1182
Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,180
Guggenheim analyst Yatin Suneja maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and adjusts the target price from $900 to $1,180.According to TipRanks data, the analyst has a
Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,040, Maintains Buy Rating
Regeneron Pharmaceuticals (REGN) has an average outperform rating and a price target range of $720 to $1,250, according to analysts polled by Capital IQ.Price: 1,087.00, Change: +1.38, Percent Change:
Express News | Regeneron Pharmaceuticals Inc : Guggenheim Raises Target Price to $1,180 From $1,040
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
In today's rapidly changing and fiercely competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies. In this article, we will conduct a
Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher by more than 100 points on Friday. Investors, meanwhile, focused on some notable insider trades.When insiders sell shares, it could be a preplanned sale, or could
CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,152
CCORF analyst John Newman maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,152.According to TipRanks data, the analyst has a success rate of 38.7%
Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
The fact that multiple Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A